drugset / Trial / NCT00082459

Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma

NCT00082459

Phase 2 Terminated 40 enrolled Agenus Inc.
RandomizedSingle-groupOpen-labelTreatment

Summary

The goal of this trial is to determine the safety of HSPPC-96 and which route of administration achieves a better response with the vaccine. HSPPC-96 is an immunotherapeutic agent made from an individual patient's tumor.

Timeline

Start
2002-07
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject vitespen Vaccine Subcutaneous

Indications